Sufferers should be educated with regard to the indicators of serious skin reactions, and use of the drug needs to be discontinued at the initial visual appearance of pores and skin rash or any other indicator of hypersensitivity.If the combination can not be averted, monitor teniposide reaction closely. Consider therapy modificationButalbital is u